Alan M. Mendelsohn

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Iain B. McInnes, Arthur Kavanaugh, Alice B. Gottlieb et al. · The Lancet · 2013 · 798 citations

Medicine, Clinical Sciences, Immunology +10

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Christopher T. Ritchlin, Proton Rahman, Arthur Kavanaugh et al. · Annals of the Rheumatic Diseases · 2014 · 658 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

Alice B. Gottlieb, Alan Menter, Alan M. Mendelsohn et al. · The Lancet · 2009 · 583 citations

Medicine, Clinical Sciences, Immunology +15

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

Arthur Kavanaugh, Christopher T. Ritchlin, Proton Rahman et al. · Annals of the Rheumatic Diseases · 2014 · 298 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Transcatheter occlusion of patent ductus arteriosus with Gianturco coils.

Thomas R. Lloyd, Raymond T. Fedderly, Alan M. Mendelsohn et al. · Circulation · 1993 · 260 citations

Medicine, Cardiology, Surgery +8